eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
State of the art paper

Cardiac parasympathetic modulation in the setting of radiofrequency ablation for atrial fibrillation

Thiago G. Osório
Gaetano Paparella
Sebastian Stec
Gian Battista Chierchia
Carlo de Asmundis

Heart Rhythm Management Centre, Postgraduate Course in Cardiac Electrophysiology and Pacing, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel, Jette, Belgium
Medinice S.A. Medi-Alfa Found, Rzeszow, Poland
Arch Med Sci
Online publish date: 2019/04/26
Article file
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero


Atrial fibrillation (AF) ablation has repeatedly proven its efficacy in the treatment of drug resistant forms of the arrhythmia [1–3]. Although, pulmonary vein isolation (PVI) is the cornerstone in today’s everyday practice, a considerable proportion of patients will recur with atrial arrhythmias following this procedure. Various strategies such as ablation of complex fractionated atrial electrograms (CFAE), ganglionated plexi, rotors, AF “nests”, or creation of lines in the left atrium have been proposed as adjunctive techniques to PVI, especially in patients affected by more advanced forms of AF [4–9]. Nevertheless, the results are controversial, and the optimal ablation strategy that might lead to significantly better results still needs to be determined.

Cardiac nervous system and atrial fibrillation

Anatomically, the cardiac nervous system can be subdivided into the extrinsic cardiac nervous system (ECNS), which contains fibers that mediate connections between the heart to the brain and the spinal cord, and the intrinsic cardiac nervous system (ICNS), composed primarily by autonomic nervous fibers, which is an interconnected neural system consisting of epicardial ganglionated plexi (GPs) (Figure 1) and an extensive network of atrial intramural microganglia [10, 11].
GPs are not merely “relay stations” for ANS projections to the heart; they contain part of the sympathetic efferent axons, almost all parasympathetic efferences, sensory afferences, and local circuit neurons, that contribute to the coordination of regional cardiac electrical and mechanical indices on a beat-to-beat basis [12].
Vagal activation might play a pivotal role in the pathogenesis of AF [13]. In 1978, a publication first proposed that AF may have a nervous system trigger [14]. Subsequently, 2 subtypes of AF were described. First subtype characterized by bradycardia and therefore defined as vagotonic AF, and second subtype induced by an increased sympathetic tone. The first subtype was often documented in young, healthy individuals, with no apparent structural heart disease; the second subtype was usually depicted in older individuals, with multiple co-morbidities and structural heart disease [15].
Various studies have shown the importance of the extrinsic and intrinsic cardiac autonomic nervous system (ICANS) innervation in the genesis and maintenance of atrial fibrillation [16–20]. With this rationale in mind, ablation of ganglionated plexi in addition to PVI has been recently proposed in order to improve clinical outcomes.
The parasympathetic postganglionic neuronal cells are found both in the paracardiac ganglia and in the cardiac wall [21, 22]. As a consequence, axons are short in length and the ablation of these structures makes parasympathetic reinnervation less likely, as the neuron body is eliminated [7] (Figures 2 and 3). This action might enable permanent ablation or attenuation of these ganglia from the endocardial surface.

Parasympathetic denervation

Parasympathetic denervation (PD) is being increasingly performed as an adjunctive ablation technique to PVI in the setting of percutaneous treatment of AF in order to potentially improve outcome [5–7, 23–25], but the success of this strategy depends on an accurate definition of the target regions and consequently, a reliable proof of denervation.
In 2005, a new technique was proposed for parasympathetic denervation (cardioneuroablation) [26] by using conventional endocardial RF ablation (Figure 3), and in 2015, a specific technique was published to confirm the vagal tone elimination just after the ablation [27].
Therefore, a reproducible technique affording a reliable evaluation of cardio-neuromodulation (cardioneuroablation) during and at the end of the procedure is mandatory [27]. Techniques aiming at specific pre-ablation mapping may be considered such as the spectral-guided ablation by fast Fourier transform (FFT) analysis [7], the simplified spectral analysis by specific filtering the RF-catheter signal in 3 channels of the traditional EP recording system [7], the high-frequency endocardial stimulation (HFS) [28, 29], the anatomic GP ablation [30, 31], and the atropine response abolition [32] (Table I).
HFS directly stimulates the neural fibers in the atrial wall [33]. Although reliable during AF, this technique might be more challenging in sinus rhythm. The difficulty of this method lies in the fact that it may be only performed in restricted areas and may cause undesired arrhythmias in case of dislodgement.
An anatomical approach for regional ablation of GPs in the right (RA) [28] and left atria (LA) [34, 35] has proven superior to selective GP ablation, controlled by HFS in maintaining patients free from AF recurrence.
Furthermore, atropine results in important autonomic changes might impede any complementary ablation in the same session. Indeed, regarding the increase of the sympathetic tone following the vagal ablation, the response to atropine has low value, as the heart rate was increased by the ablation.
The spectral analysis using the fast Fourier transform (FFT) in sinus rhythm was used for the first time to localize the insertion of nervous fibers without the need of a vagal response. The latter described 2 different types of atrial myocardium. On the one hand, the compact myocardium, with isotropic conduction, well-connected cells and a smooth spectrum, and on the other hand, the fibrillar type (AF “nests”), with a segmented spectrum and anisotropic conduction due to the afference of the nervous fibers into the myocardium. The authors introduced a new approach for the ablation of AF consisting in targeting AF nests with RF in sinus rhythm, guided by the FFT, which was hypothesized as being the real AF substrate. The mean follow-up was 9.9 ±5.0 months. After a blanking period of 3 months, 32 patients did not present recurrence of AF (94.1%) [7].
Until 2015, a reliable method to confirm the efficacy of vagal denervation following the procedure was lacking. Pachon et al. [27] proposed a simplified method to evaluate the effects of ablation on the vagal innervation by using a customized neurostimulator. In brief, direct current stimulation, with square wave pulses of 50 ms in duration at a frequency of 30 Hz and amplitude (adapted according to patient characteristics, 0.5 to 1 V/kg, limited to 70 V) between 10 to 70 V was delivered through a conventional catheter. The latter was positioned into the internal right jugular vein at the level of the upper wisdom tooth (Figure 4). This resulted in the stimulation of the vagus nerve by an endovascular electrical field. Short stimulations and minor modifications were performed to look for the optimal position corresponding to the highest response of sudden cardioinhibition (sinus arrest or bradycardia and/or atrioventricular (AV) block) induction, while preventing lesions to the surrounding tissues. Shortly after, the same protocol was performed in the left internal jugular vein. The locations corresponding to the best responses were memorized in the antero-posterior fluoroscopic projection. After having identified the ideal stimulating position, 8 to 12 s stimulation were delivered on each side. After the ablation, VS was once more performed.
The efficacy of this simplified method was described in a recent publication [27]. The authors compared a “denervation group” (DG), that underwent ablation targeting vagal tone reduction (vagal denervation for treating AF clinically related to vagal tone or severe cardioinhibitory syncope), and a “control group” (CG) submitted to ablations of conventional arrhythmias without aiming at vagal tone modification (Figure 5).
The endpoint of the procedure was characterized by the absence of any sort of vagal response in the DG. Notable cardioinhibition was obtained pre-ablation in all cases (pause of 11.5 ±1.9 s in DG vs. 11.4 ±2.1 s in CG). After ablation, cardioinhibition was reproducible only in the CG (pause of 11.2 ±2.2 s), and in all patients of the DG group in whom the ablation targeted the elimination of the AF nests, the response was completely abolished. There was no vascular injury, case of symptoms, or signs related to neurostimulation in a median (follow-up: 8.8 ±5 months) [27].


Although very promising, these results should not be generalized, and larger randomized trials are needed to confirm the abovementioned findings. However, these techniques that promote extensive vagal denervation through endocardial RF ablation might be of great value in the treatment of AF, especially in cases presenting a clear relation with the vagal tone.

Conflict of interest

The authors declare no conflict of interest.


1. Jones DG, Haldar SK, Hussain W, et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol 2013; 61: 1894-903.
2. Mont L, Bisbal F, Hernández-Madrid A, et al. Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). Eur Heart J 2014; 35: 501-7.
3. Wilber DJ, Pappone C, Neuzil P, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 2010; 303: 333-40.
4. Li WJ, Bai YY, Zhang HY, et al. Additional ablation of complex fractionated atrial electrograms after pulmonary vein isolation in patients with atrial fibrillation a meta-analysis. Circ Arrhythmia Electrophysiol 2011; 4: 143-8.
5. Nakagawa H, Scherlag BJ, Patterson E, Ikeda A, Lock-wood D, Jackman WM. Pathophysiologic basis of autonomic ganglionated plexus ablation in patients with atrial fibrillation. Hear Rhythm 2009; 6 (12 Suppl): S26-34.
6. Katritsis DG, Giazitzoglou E, Zografos T, Pokushalov E, Po SS, Camm AJ. Rapid pulmonary vein isolation combined with autonomic ganglia modification: a randomized study. Hear Rhythm 2011; 8: 672-8.
7. Pachon M JC, Pachon M EI, Pachon M JC, et al. A new treatment for atrial fibrillation based on spectral analysis to guide the catheter RF-ablation. Europace 2004; 6: 590-601.
8. Narayan SM, Krummen DE, Shivkumar K, Clopton P, Rappel WJ, Miller JM. Treatment of atrial fibrillation by the ablation of localized sources: CONFIRM (Conventional Ablation for Atrial Fibrillation with or Without Focal Impulse and Rotor Modulation) trial. J Am Coll Cardiol 2012; 60: 628-36.
9. Oral H, Chugh A, Good E, et al. Randomized comparison of encircling and nonencircling left atrial ablation for chronic atrial fibrillation. Hear Rhythm 2005; 2: 1165-72.
10. Armour JA. Cardiac neuronal hierarchy in health and disease. Am J Physiol Integr Comp Physiol 2004; 287: R262-71.
11. Pachón-Mateos JC, Pachón-Mateos EI. Letter by Pa­chón-Mateos and Pachón-Mateos regarding article, “Targets and end points in cardiac autonomic denervation procedures” and editorial, “Selective modulation of the cardiac autonomic nervous system: a new strategy for treatment of cardioinhibitory syncope”. Circ Arrhythmia Electrophysiol 2017; 10: 1-3.
12. Ardell JL, Armour JA. Neurocardiology: structure-based function. Compr Physiol 2016; 6: 1635-53.
13. Garrey E. Auricular fibrillation. Physiol Rev 1924; 4: 215-50.
14. Coumel P, Attuel P, Lavallée J, Flammang D, Leclercq JF, Slama R. The atrial arrhythmia syndrome of vagal origin. Arch Mal Coeur Vaiss 1978; 71: 645-56.
15. Coumel P. Autonomic influences in atrial tachyarrhythmias. J Cardiovasc Electrophysiol 1996; 7: 999-1007.
16. Shivkumar K, Ajijola OA, Anand I, et al. Clinical neurocardiology defining the value of neuroscience-based cardiovascular therapeutics. J Physiol 2016; 594: 3911-54.
17. Arora R. Recent insights into the role of the autonomic nervous system in the creation of substrate for atrial fibrillation implications for therapies targeting the atrial autonomic nervous system. Circ Arrhythmia Electrophysiol 2012; 5: 850-9.
18. Linz D, Ukena C, Mahfoud F, Neuberger HR, Böhm M. Atrial autonomic innervation: a target for interventional antiarrhythmic therapy? J Am Coll Cardiol 2014; 63: 215-24.
19. Ng J, Villuendas R, Cokic I, et al. Autonomic remodeling in the left atrium and pulmonary veins in heart failure creation of a dynamic substrate for atrial fibrillation. Circ Arrhythmia Electrophysiol 2011; 4: 388-96.
20. Wickramasinghe SR, Patel VV. Local innervation and atrial fibrillation. Circulation 2013; 128: 1566-75.
21. Randall WC, Milosavljevic M, Wurster RD, Geis GS, Ardell JL. Selective vagal innervation of the heart. Ann Clin Lab Sci 1986; 16: 198-208.
22. Chiou CW, Eble JN, Zipes DP. Efferent vagal innervation of the canine atria and sinus and atrioventricular nodes: the third fat pad. Circulation 1997; 95: 2573-84.
23. Lemola K, Chartier D, Yeh YH, et al. Pulmonary vein region ablation in experimental vagal atrial fibrillation: role of pulmonary veins versus autonomic ganglia. Circulation 2008; 117: 470-7.
24. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. J Interv Card Electrophysiol 2012; 33: 171-257.
25. Rosso R, Sparks PB, Morton JB, et al. Vagal paroxysmal atrial fibrillation: prevalence and ablation outcome in patients without structural heart disease. J Cardiovasc Electrophysiol 2010; 21: 489-93.
26. Pachon JC, Pachon EI, Pachon JC, et al. “Cardioneuroablation” – new treatment for neurocardiogenic syncope, functional AV block and sinus dysfunction using catheter RF-ablation. Europace 2005; 7: 1-13.
27. Pachon M JC, Pachon M EI, Santillana P TG, et al. Simplified method for vagal effect evaluation in cardiac ablation and electrophysiological procedures. JACC Clin Electrophysiol 2015; 1: 451-60.
28. Scanavacca M, Pisani CF, Hachul D, et al. Selective atrial vagal denervation guided by evoked vagal reflex to treat patients with paroxysmal atrial fibrillation. Circulation 2006; 114: 876-85.
29. Calò L, Rebecchi M, Sciarra L, et al. Catheter ablation of right atrial ganglionated plexi in patients with vagal paroxysmal atrial fibrillation. Circ Arrhythmia Electrophysiol 2012; 5: 22-31.
30. Katritsis D, Giazitzoglou E, Sougiannis D, Goumas N, Paxinos G, Camm AJ. Anatomic approach for ganglionic plexi ablation in patients with paroxysmal atrial fibrillation. Am J Cardiol 2008; 102: 330-4.
31. Piotrowski R, Baran J, Kułakowski P. Cardioneuroablation using an anatomical approach : a new and promising method for the treatment of cardioinhibitory neurocardiogenic syncope. Kardiol Pol 2018; 76: 1736-8.
32. Das G. Therapeutic review. Cardiac effects of atropine in man: an update. Int J Clin Pharmacol Ther Toxicol 1989; 27: 473-7.
33. Lemery R, Birnie D, Tang ASL, Green M, Gollob M. Feasibility study of endocardial mapping of ganglionated plexuses during catheter ablation of atrial fibrillation. Hear Rhythm 2006; 3: 387-9.
34. Pokushalov E, Romanov A, Shugayev P, et al. Selective ganglionated plexi ablation for paroxysmal atrial fibrillation. Hear Rhythm 2009; 6: 1257-64.
35. Suwalski G, Marczewska M, Kaczejko K, et al. Left atrial ganglionated plexi detection is related to heart rate and early recurrence of atrial fibrillation after surgical ablation. Brazilian J Cardiovasc Surg 2017; 32: 118-24.
Copyright: © 2019 Termedia & Banach. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe